Lonafarnib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lonafarnib" in English language version.

refsWebsite

Global rank English rank

10web.archive.org

1^st place

5nih.gov

4^th place

4europa.eu

68^th place

117^th place

4fda.gov

447^th place

338^th place

3doi.org

2^nd place

1semanticscholar.org

11^th place

8^th place

1progeriaresearch.org

low place

1cancer.gov

1,684^th place

1,350^th place

cancer.gov

"Lonafarnib". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 5 November 2013. Retrieved 5 November 2013.

doi.org

Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, et al. (June 2022). "A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis". Hepatology. 75 (6): 1551–1565. doi:10.1002/hep.32259. PMID 34860418.
Liu G, Marrinan CH, Taylor SA, Black S, Basso AD, Kirschmeier P, et al. (September 2007). "Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)". Anti-Cancer Drugs. 18 (8): 923–31. doi:10.1097/CAD.0b013e3280c1416e. PMID 17667598. S2CID 7009843.
Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, et al. (July 2013). "Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment". Neurology. 81 (5): 427–30. doi:10.1212/WNL.0b013e31829d85c0. PMC 3776537. PMID 23897869.

europa.eu

ema.europa.eu

"Zokinvy EPAR". European Medicines Agency. 17 May 2022. Archived from the original on 2 August 2022. Retrieved 1 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Zokinvy: Pending EC decision". European Medicines Agency. 19 May 2022. Archived from the original on 20 May 2022. Retrieved 20 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"First treatment for children with Progeria or progeroid like syndromes (rare premature aging syndromes)". European Medicines Agency (EMA) (Press release). 19 May 2022. Archived from the original on 20 May 2022. Retrieved 20 May 2022.

ec.europa.eu

"Zokinvy Product information". Union Register of medicinal products. Retrieved 3 March 2023.

fda.gov

"FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies". U.S. Food and Drug Administration (FDA) (Press release). 20 November 2020. Archived from the original on 28 November 2020. Retrieved 20 November 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Zokinvy". U.S. Food and Drug Administration. 20 November 2020. Archived from the original on 12 December 2020. Retrieved 11 December 2020. This article incorporates text from this source, which is in the public domain.
"New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Zokinvy". U.S. Food and Drug Administration (FDA). 18 December 2020. Archived from the original on 22 January 2021. Retrieved 17 January 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, et al. (June 2022). "A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis". Hepatology. 75 (6): 1551–1565. doi:10.1002/hep.32259. PMID 34860418.
Liu G, Marrinan CH, Taylor SA, Black S, Basso AD, Kirschmeier P, et al. (September 2007). "Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)". Anti-Cancer Drugs. 18 (8): 923–31. doi:10.1097/CAD.0b013e3280c1416e. PMID 17667598. S2CID 7009843.
Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, et al. (July 2013). "Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment". Neurology. 81 (5): 427–30. doi:10.1212/WNL.0b013e31829d85c0. PMC 3776537. PMID 23897869.

dailymed.nlm.nih.gov

"Lonafarnib capsule". DailyMed. Archived from the original on 22 January 2021. Retrieved 17 January 2021.

ncbi.nlm.nih.gov

Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, et al. (July 2013). "Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment". Neurology. 81 (5): 427–30. doi:10.1212/WNL.0b013e31829d85c0. PMC 3776537. PMID 23897869.

progeriaresearch.org

"The FTI Drug Lonafarnib" Archived 15 December 2021 at the Wayback Machine, Progeria Research Foundation. Accessed 3 October 2017.

semanticscholar.org

api.semanticscholar.org

Liu G, Marrinan CH, Taylor SA, Black S, Basso AD, Kirschmeier P, et al. (September 2007). "Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)". Anti-Cancer Drugs. 18 (8): 923–31. doi:10.1097/CAD.0b013e3280c1416e. PMID 17667598. S2CID 7009843.

web.archive.org

"Lonafarnib capsule". DailyMed. Archived from the original on 22 January 2021. Retrieved 17 January 2021.
"Zokinvy EPAR". European Medicines Agency. 17 May 2022. Archived from the original on 2 August 2022. Retrieved 1 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies". U.S. Food and Drug Administration (FDA) (Press release). 20 November 2020. Archived from the original on 28 November 2020. Retrieved 20 November 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Zokinvy". U.S. Food and Drug Administration. 20 November 2020. Archived from the original on 12 December 2020. Retrieved 11 December 2020. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Zokinvy". U.S. Food and Drug Administration (FDA). 18 December 2020. Archived from the original on 22 January 2021. Retrieved 17 January 2021.
"New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
"Zokinvy: Pending EC decision". European Medicines Agency. 19 May 2022. Archived from the original on 20 May 2022. Retrieved 20 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"First treatment for children with Progeria or progeroid like syndromes (rare premature aging syndromes)". European Medicines Agency (EMA) (Press release). 19 May 2022. Archived from the original on 20 May 2022. Retrieved 20 May 2022.
"The FTI Drug Lonafarnib" Archived 15 December 2021 at the Wayback Machine, Progeria Research Foundation. Accessed 3 October 2017.
"Lonafarnib". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 5 November 2013. Retrieved 5 November 2013.